00869nas a2200373   4500000000100000000000100001008004100002100001400043700001400057700001200071700001400083700001300097700001500110700001700125700001600142700001600158700001300174700001300187700001600200700001300216700001400229700001100243700001500254700001600269700001400285700001600299700001600315700001500331700001300346245010300359300001200462490000700474022001400481       2012                            d1 a3rd. Re V1 aK. Haynes1 aE. Ming1 aWood Ives1 aL. Horne1 aK. Fortier1 aD. Carbonari1 aS. Hennessy1 aS. Cardillo1 aP. Reese1 aK. Reddy1 aD. Margolis1 aA. Apter1 aS. Kimmel1 aJ. Roy1 aC. Freeman1 aH. Razzaghi1 aC. Holick1 aD. Esposito1 aT. van Staa1 aH. Bhullar1 aB. Strom00aSafety of saxagliptin: rationale for and design of a series of postmarketing observational studies  a1202-150 v21  a1053-8569